SELLEST OSAST
When did drug developers become the bad guys?
Will Soliman sits down with Anna Rose Welch, Editor of Advancing RNA, for a candid discussion on what the public often gets wrong about biotechnology and the people developing tomorrow’s medicines.
From RNA therapeutics and mRNA to gene editing, AI, precision medicine, regulation, reimbursement, and the race to bring new therapies to patients, Anna shares what she is hearing from the scientists, executives, and innovators working at the leading edge of drug development. They also examine why breakthrough science can struggle to earn public trust, why communication matters as much as innovation, and where RNA-based medicines may have their greatest impact over the next decade.
A conversation about the science, the skepticism, and what biotech insiders are seeing before it reaches the headlines.
To Learn More, Visit These Related Sites:
- Accreditation Council for Medical Affairs
- Medical Science Liaisons
- Prior Authorization and Field Reimbursement
- White Manna Capital Partners
Have a Topic or Guest Suggestion: Contact Us
🎙️ Spotify
🎙️ YouTube
🎙️ Amazon Music
🎙️ iHeart Radio
RNA Therapeutics, mRNA, Drug Development, Biotechnology, Precision Medicine, AI in Healthcare, Biopharma, Life Sciences, Medical Innovation, William Soliman, Anna Rose Welch, Advancing RNA, ACMA, Accreditation Council for Medical Affairs
